1. Home
  2. AWK vs BIIB Comparison

AWK vs BIIB Comparison

Compare AWK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AWK
  • BIIB
  • Stock Information
  • Founded
  • AWK 1886
  • BIIB 1978
  • Country
  • AWK United States
  • BIIB United States
  • Employees
  • AWK N/A
  • BIIB N/A
  • Industry
  • AWK Water Supply
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • AWK Utilities
  • BIIB Health Care
  • Exchange
  • AWK Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • AWK 27.5B
  • BIIB 18.8B
  • IPO Year
  • AWK 2008
  • BIIB 1991
  • Fundamental
  • Price
  • AWK $142.24
  • BIIB $133.99
  • Analyst Decision
  • AWK Hold
  • BIIB Buy
  • Analyst Count
  • AWK 10
  • BIIB 27
  • Target Price
  • AWK $143.10
  • BIIB $188.17
  • AVG Volume (30 Days)
  • AWK 1.1M
  • BIIB 1.3M
  • Earning Date
  • AWK 07-30-2025
  • BIIB 07-31-2025
  • Dividend Yield
  • AWK 2.33%
  • BIIB N/A
  • EPS Growth
  • AWK 11.78
  • BIIB 26.39
  • EPS
  • AWK 5.49
  • BIIB 10.12
  • Revenue
  • AWK $4,815,000,000.00
  • BIIB $9,816,400,000.00
  • Revenue This Year
  • AWK $7.60
  • BIIB N/A
  • Revenue Next Year
  • AWK $6.63
  • BIIB N/A
  • P/E Ratio
  • AWK $25.91
  • BIIB $13.29
  • Revenue Growth
  • AWK 11.79
  • BIIB 1.59
  • 52 Week Low
  • AWK $118.74
  • BIIB $110.04
  • 52 Week High
  • AWK $155.50
  • BIIB $238.00
  • Technical
  • Relative Strength Index (RSI)
  • AWK 53.41
  • BIIB 56.84
  • Support Level
  • AWK $137.00
  • BIIB $129.08
  • Resistance Level
  • AWK $143.66
  • BIIB $137.84
  • Average True Range (ATR)
  • AWK 2.51
  • BIIB 4.01
  • MACD
  • AWK 0.32
  • BIIB 0.57
  • Stochastic Oscillator
  • AWK 74.80
  • BIIB 70.81

About AWK American Water Works Company Inc.

American Water Works is the largest investor-owned US water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's nonregulated business is water services for military bases, which operates under long-term contracts with regulated-like returns.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Share on Social Networks: